Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy

Small bowel adenocarcinoma is a rare gastrointestinal malignancy that accounts for fewer than 3% of all gastrointestinal cancers and is associated with poor prognosis. Most patients are diagnosed at an advanced stage because lesions in the distal duodenum, jejunum, and ileum are difficult to detect endoscopically, and symptoms such as anemia, obstruction, or bleeding often appear only after the disease has progressed. For patients with locally advanced or metastatic small bowel adenocarcinoma, fluoropyrimidine plus oxaliplatin regimens such as FOLFOX and CapeOX are widely used as first-line systemic therapy. Prospective studies have reported objective response rates of approximately 40-50% and median overall survival of about 13-20 months with these platinum-based combinations. However, there is no established standard of care beyond first-line treatment, and outcomes after failure of platinum-based chemotherapy are dismal, with small retrospective series suggesting modest activity of regimens such as irinotecan-based chemotherapy or taxanes and very low response rates in routine practice. In the absence of targetable alterations qualifying for tumor-agnostic approved therapies, best supportive care remains the default recommendation for many patients after failure of first-line therapy.

Enfortumab vedotin is an antibody-drug conjugate composed of a fully human IgG1κ monoclonal antibody directed against the cell adhesion molecule Nectin-4, linked via a protease-cleavable linker to the microtubule inhibitor monomethyl auristatin E. Binding of enfortumab vedotin to Nectin-4 on the tumor cell surface leads to internalization of the antibody-drug conjugate and intracellular release of monomethyl auristatin E, resulting in disruption of tubulin polymerization, cell-cycle arrest at the G2/M phase, and apoptotic cell death. Non-clinical studies have shown high-affinity and selective binding to Nectin-4, Nectin-4-dependent intracellular delivery of monomethyl auristatin E, direct cytotoxicity against Nectin-4-positive tumor cells, and bystander killing of adjacent Nectin-4-negative cells. In clinical trials in patients with urothelial carcinoma, the same schedule used in this trial (1.25 mg/kg intravenously on days 1, 8, and 15 of a 28-day cycle) has demonstrated clinically meaningful antitumor activity and an acceptable safety profile in phase I-III studies, leading to regulatory approval in that indication.

There are no published clinical data for enfortumab vedotin in small bowel adenocarcinoma. To address this gap, the National Cancer Center Hospital conducted immunohistochemical analyses of Nectin-4 in tumor samples from patients with small bowel adenocarcinoma. Among 51 consecutively diagnosed cases, Nectin-4 expression was detected in 42 tumors (82.4%). In patients who received palliative chemotherapy, Nectin-4 positivity was associated with significantly shorter overall survival compared with Nectin-4-negative disease (median 12.6 vs 43.2 months), and higher levels of Nectin-4 expression tended to correlate with worse outcomes. In multivariable analysis, poor performance status and Nectin-4 positivity were both identified as independent adverse prognostic factors. These findings suggest that Nectin-4 is both highly expressed and prognostically unfavorable in small bowel adenocarcinoma, providing a strong biological rationale to investigate Nectin-4-targeted therapy in this setting.

This investigator-initiated study is a prospective, multicenter, open-label, single-arm Phase II trial designed to evaluate the antitumor activity and safety of enfortumab vedotin in adults with locally advanced or metastatic small bowel adenocarcinoma that is refractory or intolerant to platinum-based combination therapy. Eligible patients must have histologically or cytologically confirmed small bowel adenocarcinoma that is unresectable, metastatic, or recurrent after prior curative surgery, Eastern Cooperative Oncology Group performance status 0-1, at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on contrast-enhanced computed tomography within 14 days before registration, and prior treatment with FOLFOX or CapeOX with documented progression, recurrence, or discontinuation due to toxicity. Where prior comprehensive genomic testing has identified alterations qualifying for tumor-agnostic approved therapies (for example, high microsatellite instability or mismatch-repair deficiency, BRAF V600E mutation), patients must be refractory or intolerant to such therapies. Nectin-4 expression is not required for enrollment, in line with experience in urothelial carcinoma, where benefit has been observed regardless of Nectin-4 level. Key exclusion criteria include active or prior interstitial lung disease, poorly controlled diabetes, clinically significant ocular surface disease, and uncontrolled comorbidities that could compromise protocol therapy.

Enfortumab vedotin will be administered at a dose of 1.25 mg/kg as an intravenous infusion on days 1, 8, and 15 of each 28-day cycle. Treatment will be continued until radiographic or clinical disease progression, unacceptable toxicity, withdrawal of consent. Dose delays, interruptions, and stepwise dose reductions are specified to manage treatment-related toxicities, particularly peripheral neuropathy, skin reactions, and metabolic adverse events, based on experience from prior trials in urothelial carcinoma. Supportive care measures, including antiemetics, analgesics, nutritional support, and local radiotherapy for symptom control, are permitted according to institutional practice, while concurrent antineoplastic therapies other than the study drug are prohibited.

Tumor assessments with contrast-enhanced CT of the chest, abdomen, and pelvis will be performed every 8 weeks up to week 24 and every 12 weeks thereafter, or as clinically indicated, until documented disease progression. The best overall response and objective response rate will be evaluated according to RECIST version 1.1 by a blinded, independent central review committee, with local investigator assessments also collected for the secondary endpoint. Safety will be monitored throughout treatment and for a predefined follow-up period, with adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events. Particular attention will be paid to skin toxicity, peripheral neuropathy, hyperglycemia, and ocular events, which have been identified as important adverse drug reactions for enfortumab vedotin in other tumor types. An independent committee will periodically review accumulating safety and efficacy data to support ongoing risk-benefit evaluation.

The primary efficacy endpoint is the objective response rate based on blinded independent central review in the full analysis set. The statistical design is an exact binomial single-stage phase II design with a null hypothesis objective response rate of 5%, reflecting the limited activity of existing second-line options, and an expected objective response rate of 25% for enfortumab vedotin. With a one-sided alpha of 0.05 and 90% power, 25 evaluable patients are required; allowing for a small number of non-evaluable cases, the planned sample size is 27 patients. Secondary endpoints include investigator-assessed objective response rate, disease control rate, progression-free survival, overall survival, duration of response, time to response, and safety outcome.

A prespecified translational research program is embedded in the trial. Archival tumor tissue or a pretreatment biopsy is required for enrollment whenever feasible. Tumor Nectin-4 expression will be evaluated centrally by immunohistochemistry, and exploratory analyses will investigate the association between Nectin-4 expression levels and clinical outcomes with enfortumab vedotin. Additionally, blood and tissue biospecimens will be collected at baseline, during treatment, and at disease progression, where possible, for multi-omics analyses. These studies aim to elucidate the mechanisms of sensitivity and resistance, identify predictive and prognostic biomarkers, and generate hypotheses for subsequent biomarker-driven trials in small bowel adenocarcinoma.

The trial is conducted under the oversight of a central coordinating committee, in accordance with the Declaration of Helsinki and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice guidelines. The protocol has been approved by the institutional review board of the lead institution and by ethics committees at all participating sites. Written informed consent will be obtained from all participants before any study-specific procedures.